Experienced in Melanoma

Dr. Jonathan R. Whisenant

Oncology
5131 Cottonwood St, Bldg 3 Level 2, 
Murray, UT 
Accepting New Patients
Offers Telehealth
Experienced in Melanoma
5131 Cottonwood St, Bldg 3 Level 2, 
Murray, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jonathan Whisenant is an Oncologist in Murray, Utah. Dr. Whisenant is rated as an Experienced provider by MediFind in the treatment of Melanoma. His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Gastrointestinal Stromal Tumor, Colorectal Cancer, and Familial Colorectal Cancer. Dr. Whisenant is currently accepting new patients.

His clinical research consists of co-authoring 20 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Melanoma.

Graduate Institution
UCSF Medical School
Residency
University Of Colorado At Denver
Specialties
Oncology
Licenses
Internal Medicine in UT
Board Certifications
Internal Medicine-American Board Of Internal Medicine
Medical Oncology-American Board Of Internal Medicine (ABIM)
Fellowships
University of CA at San Francisco School of Medicine
Hospital Affiliations
Riverton Hospital
Alta View Hospital
Intermountain Medical Center
Utah Valley Hospital
LDS Hospital
American Fork Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Intermountain Medical Center
5131 Cottonwood St, Bldg 3 Level 2, Murray, UT 84107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2025
Intervention Type: Device, Biological, Other, Drug
Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab
Study Phase: Phase 2
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Other, Drug
Study Drug: Trametinib
Study Phase: Phase 2
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: August 01, 2023
Intervention Type: Biological
Study Drug: Enapotamab vedotin 
Study Phase: Phase 1/Phase 2
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)
Enrollment Status: Completed
Publish Date: January 11, 2023
Intervention Type: Drug, Biological
Study Drugs: PDR001, LCL161, Everolimus, Panobinostat, QBM076, HDM201
Study Phase: Phase 1
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Other
Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma
Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma
Enrollment Status: Terminated
Publish Date: June 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I Open Label Trial of a Combination of Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma
A Phase I Open Label Trial of a Combination of Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma
Enrollment Status: Terminated
Publish Date: December 12, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

20 Total Publications

Author Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
Author Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
Journal: Nature medicine
Published: April 25, 2025
Similar Doctors
Kenneth F. Grossmann
Elite in Melanoma
Dr. Kenneth F. Grossmann
Oncology
Elite in Melanoma
Dr. Kenneth F. Grossmann
Oncology
2000 Circle Of Hope, Clinic 2b, 
Salt Lake City, UT 
 (7.7 miles away)
801-585-0100
Languages Spoken:
English
See accepted insurances

Kenneth Grossmann is an Oncologist in Salt Lake City, Utah. Dr. Grossmann is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Lung Cancer, Pleuropulmonary Blastoma, and Merkel Cell Carcinoma.

Elite in Melanoma
Dr. Siwen Hu
Hematology | Oncology
Elite in Melanoma
Dr. Siwen Hu
Hematology | Oncology

University Of Utah Adult Services

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (8.4 miles away)
801-581-8793
Languages Spoken:
English
See accepted insurances

Siwen Hu is a Hematologist and an Oncologist in Salt Lake City, Utah. Dr. Hu is rated as an Advanced provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Melanoma, Melanoma of the Eye, Non-Small Cell Lung Cancer (NSCLC), and Neuroendocrine Tumor.

Advanced in Melanoma
Dr. David M. Gill
Oncology
Advanced in Melanoma
Dr. David M. Gill
Oncology

Intermountain Health Cancer Center - Murray

5171 South Cottonwood Street, Suite 610, 
Murray, UT 
 (0.5 miles away)
801-507-3630
Experience:
12+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Gill is an Oncologist in Murray, Utah. Dr. Gill has been practicing medicine for over 12 years and is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Prostate Cancer, Upper Tract Urothelial Carcinoma (UTUC), Familial Prostate Cancer, Orchiectomy, and Prostatectomy. Dr. Gill is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Whisenant's expertise for a condition
ConditionClose
    View All 39 Advanced Conditions
    View All 96 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile